Around a quarter of the global population is estimated to have been infected with Mycobacterium tuberculosis (Mtb), with 5-10% of those developing active disease during their lifetimes. New next-generation skin tests use antigens specific to Mtb to accurately detect infection. Unlike the tuberculin-based Mantoux skin test, these new skin tests are not affected by prior BCG (bacille Calmette-Guérin) vaccination. Testing for Mtb infection before TB preventive treatment is particularly of use for people who are household contacts of people with TB or from other risk groups.
The introducing New Tools Project will pilot the SIILTIBCY (Cy-Tb) skin test in 2 countries in 2025.
Availability through Stop TB Partnership's GDF
SIILTIBCY is available through the Stop TB Partnership’s Global Drug Facility (GDF).
For more information, see the GDF Medicines Catalog and the GDF Info Sheet on SIILTIBCY.